학술논문

The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland
Document Type
Article
Source
In Clinical Oncology May 2024 36(5):287-299
Subject
Language
ISSN
0936-6555